LIMN

Liminatus Pharma, Inc. Class A Common Stock

NASDAQ: LIMN · HEALTHCARE · BIOTECHNOLOGY

$3.47

-4.41% today

Updated 2026-09-11

Market cap

$4.97M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-24.00

Dividend yield

—

52W range

$3 – $142

Volume

40.0M

Market cap

$4.97M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-24.00

Dividend yield

—

52W range

$3 – $142

Volume

40.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

2.5

Quality

3.5

Profitability

5.0

Valuation

C+

1/9

Piotroski F-Score

Weak

-193.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →251 stocks currently score above 75

Price targets

Analyst target

—

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Piotroski 1/9 — weak financial health

- Altman Z -193.35 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-969999.00

- Debt/equity 4.80x — high leverage

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	—
Net income	$-2.93M	$-1.23M	$-2.90M	$-10.21M	$-1.41M
EPS	—	—	—	—	$-24.00
Free cash flow	$-869000.00	$-3.35M	$-3.11M	$-9.98M	$-969999.00
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LIMN	$4.97M	17	4.3	3.5	5.0	2.5	—	Avoid
LLY	$994.92B	76	9.3	10.0	5.0	6.0	—	Strong Buy
JNJ	$640.02B	59	4.7	8.5	2.7	6.0	-88.93%	Buy
ABBV	$454.36B	73	6.7	8.5	4.0	5.0	-69.36%	Strong Buy
MRK	$355.10B	36	4.0	4.5	2.0	5.0	-73.74%	Hold
UNH	$340.27B	62	7.3	5.5	4.7	6.0	-16.10%	Buy

Smart narrative

Liminatus Pharma, Inc. Class A Common Stock trades at $3.47. Our Smart Value Score of 17/100 indicates the stock is weak. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of -193.35, it sits in the distress.

Frequently asked questions

What is Liminatus Pharma, Inc. Class A Common Stock's stock price?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) trades at $3.47.

Is Liminatus Pharma, Inc. Class A Common Stock overvalued?

Liminatus Pharma, Inc. Class A Common Stock carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

Altman Z-Score?

Liminatus Pharma, Inc. Class A Common Stock's Altman Z-Score is -193.35, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

liminatuspharma.com

Quick metrics

P/S ratio—

ROE—

Beta0.74

50D MA$5.56

200D MA$18.96

Shares out0.00B

Float0.00B

Short ratio—

Avg volume40.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

LIMN vs LLY →LIMN vs JNJ →LIMN vs ABBV →Stock screener →